The study was stopped due to insufficient recruitment.

The study population has locally advanced or metastatic bronchial or head and neck cancer.

This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during metastatic radiotherapy versus radiotherapy alone.

The realization of a systemic treatment during the radiotherapy could make it possible to obtain a benefit on the control of the evolution of the metastases and thus of the pains generated, as well as on the quality of life of the patients. In addition, a benefit in overall survival is possible.

The study population has locally advanced or metastatic bronchial or head and neck cancer.

Patients receive 10 injections of carboplatin (validated chemo-sensitizing molecule) or placebo (glucose) before 10 radiation sessions.

The overall duration is 14 days.

Inclusion Criteria:

• Patients with locally advanced or metastatic bronchial or head and neck cancer
• Patient require palliative radiotherapy
• Age ≥ 18 years
• PS ≤ 2
• Obtaining the signed written consent of the patient
• Patient affiliated to a social security scheme

Exclusion Criteria:

• Other chemotherapy or targeted therapy
• Prior radiation
• Patients with thrombopenia < 100 000
• Patients with neutropenia < 2000
• Patients with renal clearance < 20 mL/min
• Known hypersensitivity to platinum salt
• Treatment with phenytoin or fosphenytoin
• In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine
• Unchecked diabetes
• hemorrhagic tumor
• Refusal of participation or inability to issue informed consent
• Person deprived of liberty or adult under guardianship
• Minor patients, pregnant or lactating women
• Participation in other interventional study